Big Test for NeuroMetrix

NeuroMetrix (NURO Quote) has some nerves to calm.

The company, which markets a painless but controversial nerve test, could soothe rattled investors when it reports first-quarter results on Tuesday. But bears, who have sold more than half of NeuroMetrix shares short, believe the company could leave fans feeling even jumpier.

"I'm actually on the edge of my seat with respect to these numbers because I think they could be pretty bad," one short seller told TheStreet.com on Monday. "I think they lose money on an earnings-per-share basis and go negative on cash flow from operations." ...